China Shineway Pharmaceutical Group Limited
CSWYF · OTC
12/31/2024 | 6/30/2024 | 12/31/2023 | 6/30/2023 | |
|---|---|---|---|---|
| Revenue | $3,490,912 | $287,131 | $145,039 | $174,637 |
| % Growth | 1,115.8% | 98% | -16.9% | – |
| Cost of Goods Sold | $875,497 | $70,797 | $36,139 | $43,299 |
| Gross Profit | $2,615,415 | $216,334 | $108,900 | $131,338 |
| % Margin | 74.9% | 75.3% | 75.1% | 75.2% |
| R&D Expenses | $94,365 | $6,157 | $4,264 | $3,509 |
| G&A Expenses | $271,339 | $19,981 | $12,884 | $10,074 |
| SG&A Expenses | $1,755,583 | $133,042 | $78,332 | $85,165 |
| Sales & Mktg Exp. | $1,484,834 | $112,471 | $65,503 | $74,637 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,849,948 | $139,199 | $73,109 | $86,574 |
| Operating Income | $765,467 | $77,135 | $26,304 | $42,664 |
| % Margin | 21.9% | 26.9% | 18.1% | 24.4% |
| Other Income/Exp. Net | $261,631 | $41,488 | $12,661 | $6,209 |
| Pre-Tax Income | $1,027,098 | $118,623 | $38,965 | $48,874 |
| Tax Expense | $273,250 | $32,419 | $6,227 | $13,092 |
| Net Income | $753,848 | $86,204 | $32,738 | $35,781 |
| % Margin | 21.6% | 30% | 22.6% | 20.5% |
| EPS | 0.996 | 0.114 | 0.043 | 0.047 |
| % Growth | 772% | 165% | -8.9% | – |
| EPS Diluted | 0.996 | 0.114 | 0.043 | 0.047 |
| Weighted Avg Shares Out | 755,400 | 755,400 | 758,802 | 756,100 |
| Weighted Avg Shares Out Dil | 755,400 | 755,400 | 755,400 | 755,400 |
| Supplemental Information | – | – | – | – |
| Interest Income | $176,718 | $0 | $3,173 | $4,109 |
| Interest Expense | $5,338 | $791 | $0 | $0 |
| Depreciation & Amortization | $57,634 | $11,101 | $5,464 | $6,269 |
| EBITDA | $1,132,349 | $88,236 | $31,768 | $48,933 |
| % Margin | 32.4% | 30.7% | 21.9% | 28% |